Property:Specifications on cancer therapies
This is a property of type Text.
L
Lyckholm et al. (2012): A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders +
14 patients were receiving or had received radiation therapy +
M
Mahmoodnia et al. (2017): Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients +
Cisplatin-chemotherapy +
Mansouri et al. (2016): The Effect of Aloe Vera Solution on Chemotherapy-Induced Stomatitis in Clients with Lymphoma and Leukemia: A Randomized Controlled Clinical Trial +
NI +
Mansourian et al. (2015): The effect of "curcuma Longa" topical gel on radiation -induced oral mucositis in patients with head and neck cancer +
NI +
Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia +
Concomitant antineoplastic palliative chemotherapy in 77.1-81.8% of patients per arm, NI on percentage of patients receiving hormone therapy +
Margalit et al. (2012): Beta-carotene Antioxidant Use During Radiation Therapy and Prostate Cancer Outcome in the Physicians’ Health Study +
Radiation type per group:
- intervention: 129x external beam radiation, 39x brachytherapy, 21x both, 2x unknown or missing
- placebo: 133x external beam radiation, 40x brachytherapy, 16x both, 3x unknown or missing +
Martin et al. (2002): Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial +
Curative surgery per arm for:
23 carcinomas of the rectosigmoid
(enzyme arm: 9; placebo arm: 14)
17 endometrial carcinoma
(enzyme arm: 8; placebo arm: 9)
14 uterine cervix cancer
(enzyme arm: 11; placebo arm: 3),
1 carcinoma of the vulva
(enzyme arm: 0; placebo arm: 1)
1 prostate cancer
(enzyme arm: 0; placebo arm: 1) +
Marucci et al. (2017): Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer +
Treatment intent:
Definitive = 86
Postoperative = 18
Induction chemotherapy:
Yes = 96
No = 8 +
Marx et al. (2017): The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial +
NI +
Mayne et al. (2001): Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer +
NI +
Mazdak et al. (2012): Vitamin E reduces superficial bladder cancer recurrence: A randomized controlled Trial +
No intravesical chemotherapy +
Meyskens et al. (1995): Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial +
''Intermittent pulse busulfan:''
"All patients received busulfan orally at a dose of 8 mg/mm³/day for 4 days every 4 weeks until a chronic stable phase was reached (total leukocyte count <50,000/mm³ but >6,000/mm³) at which time busulfan was discontinued. Busulfan was restarted only when the total leukocyte count exceeded 5O,OOO/mm³. Treatment was reinstated until the total leukocyte count was <50,000 but >6,000." +
Minchom et al. (2014): An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of (...) +
- Current chemotherapy: platinum-based treatment with cisplatin (up to six cycles)
- Palliative radiation therapy permitted for irradiating small areas of painful metastases that could not be managed adequately using systemic or local analgesia
- Patients were allowed to receive full supportive care therapies concomitantly, except for growth factors as a prophylactic measure, during the study +
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck +
Radiotherapy: 70 Gy at 2 Gy per fraction in 35 daily treatments, 5 days a week for 7 weeks, chemotherapy: Cisplatin dosed at 100 mg/m² intravenously over 3h in 1000mL saline on days 1, 22, and 43 of radiotherapy +
Mondal et al. (2014): Comparative study among glutamine, acetyl-L-carnitine, vitamin-E and methylcobalamine for treatment of paclitaxel-induced peripheral neuropathy +
With paclitaxel as first or second line treatment +
Montazeri et al. (2013): Effect of Herbal Therapy to Intensity Chemotherapy-Induced Nausea and Vomiting in Cancer Patients +
In: ≥2 cycles of cisplatin chemotherapy
Chemoregime: 50-100 mg cisplatin +/- others +
Montazeri et al. (2013): Iranian Red Crescent Medical JournalEffect of Herbal Therapy to Intensity Chemotherapy-Induced Nausea and Vomiting in Cancer Patients. +
? +
Moslemi et al. (2014): Oral zinc sulphate and prevention of radiation-induced oropharyngealmucositis in patients with head and neck cancers: A double blind, randomized controlled clinical trial +
Radiotherapy doses (cGy) Range: 4000-7000;
concurrent chemoradiotherapy: n=32 +
Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology +
External radiotherapy was delivered with a 6- to 18-MV linear accelerator.
Five fractions per week were planned. Treatment was given with a three- to four-field box technique. Radiotherapy was given as three-dimensional conformal radiotherapy. Computed tomography–based treatment planning was performed in all cases. The clinical target volume encompassed the primary tumor region and the pelvic regional lymph nodes. High-dose rate brachytherapy of the vagina was considered optional in accordance with German evidence-based guidelines. Brachytherapy was delivered by iridium 192 afterloading. +
Muecke et al. (2013): Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology-a subgroup analysis of a multicenter, phase III trial +
External radiotherapy was delivered with a 6- to 18-MV linear accelerator. Five fractions per week were planned. Treatment was given with a three- to four-field box technique. Radiotherapy was given as three-dimensional conformal radiotherapy. Computed tomography–based treatment planning was performed in all cases. The clinical target volume encompassed the primary tumor region and the pelvic regional lymph nodes. High-dose rate brachytherapy of the vagina was considered optional in accordance with German evidence-based guidelines. Brachytherapy was delivered by iridium 192 afterloading. +